Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 17/20 | 0.56 |
| ▸ | JAK1 | P23458 | 11/20 | 0.56 |
| ▸ | JAK2 | O60674 | 7/20 | 0.56 |
| ▸ | TYK2 | P29597 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24121894 | 0.98 | JAK3 (0.58) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL13961118 | 0.98 | JAK3 (0.58) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL24121887 | 0.94 | KIT (0.54) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL1093969 | 0.93 | HPGDS (0.53) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL24121677 | 0.92 | KIT (0.52) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL24121893 | 0.91 | JAK3 (0.49) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL24121881 | 0.87 | JAK3 (0.50) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL24121892 | 0.87 | HPGDS (0.47) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL24121882 | 0.85 | JAK3 (0.49) | HPGDSJAK3JAK1JAK2TYK2 | |
| SCHEMBL28345670 | 0.85 | JAK3 (0.59) | HPGDSJAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-23 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| EP-1844050-B1 | PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1844050-B1 | PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| CN-101142218-A | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMA (US) | 2008-03-12 | — | — | CN | disclosed |
| EP-1844050-A1 | PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | Vertex Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
| WO-2006096270-A1 | PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060183761-A1 | Pyrrolopyrimidines useful as inhibitors of protein kinase | LEDEBOER MARK | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | HPGDS 118/4885JAK3 61/4885JAK1 12/4885 |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | HPGDS 930/4885JAK3 279/4885JAK1 182/4885 |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | HPGDS 434/4885JAK3 2/4885JAK1 1/4885 |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | HPGDS 434/4885JAK3 2/4885JAK1 1/4885 |
| US-20060183761-A1 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | HPGDS 930/4885JAK3 279/4885JAK1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.